Pharmacokinetic Changes during Pregnancy According to Genetic Variants: a Prospective Study in HIV-Infected Patients Receiving Atazanavir-Ritonavir

Antimicrobial Agents and Chemotherapy
Emanuele FocàStefano Bonora

Abstract

Atazanavir-ritonavir concentrations change over time during pregnancy in HIV-positive patients; the impact of genetic variants is unknown. Twenty patients were enrolled in this study; plasma and intracellular concentrations of antiretrovirals were measured, in addition to single-nucleotide polymorphisms in transport-related genes. Linear logistic regression showed that genetic variants in organic-anion-transporter-1B1- and pregnane-X-receptor-encoding genes affected third-trimester atazanavir exposure. In this prospective study, genetic variants partially explained the observed interpatient variability in third-trimester exposure to antiretrovirals.

References

Sep 18, 2002·Antimicrobial Agents and Chemotherapy·Saye H KhooDavid J Back
Jul 2, 2004·Therapeutic Drug Monitoring·Michel EichelbaumMatthias Schwab
Oct 16, 2004·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Marta BoffitoAnton Pozniak
Nov 13, 2004·The Journal of Antimicrobial Chemotherapy·J FordD J Back
Aug 31, 2006·Antimicrobial Agents and Chemotherapy·Sara ColomboChantal Csajka
Oct 4, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Marco SiccardiAndrew Owen
Jan 19, 2010·British Journal of Clinical Pharmacology·Fabiana B KohlrauschGuilherme Suarez-Kurtz
Mar 1, 2012·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Shujuan ChenRobert H Tukey
Sep 30, 2017·The Journal of Antimicrobial Chemotherapy·Emanuele FocàStefano Bonora

❮ Previous
Next ❯

Citations

Apr 10, 2020·Expert Opinion on Drug Metabolism & Toxicology·Megan NearyAdeniyi Olagunju
Jul 2, 2021·Biochimica Et Biophysica Acta. Molecular Basis of Disease·Lukas CervenyFrantisek Staud

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.